Cypherpunk Technologies (CYPH) Stock Overview
A biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CYPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cypherpunk Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$3.58 |
| 52 Week Low | US$0.22 |
| Beta | 0.086 |
| 1 Month Change | 182.05% |
| 3 Month Change | 556.47% |
| 1 Year Change | -35.77% |
| 3 Year Change | -70.95% |
| 5 Year Change | -88.19% |
| Change since IPO | -97.76% |
Recent News & Updates
Recent updates
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?
Mar 13
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?
Nov 22Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
Aug 12Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers
Jul 12Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Jun 27Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation
May 01Leap Therapeutics: Waiting For One More Leap
Feb 18We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely
Jan 04Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Nov 29Leap Therapeutics: All On The Line
Oct 13Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Sep 15Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Jun 01Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth
Mar 03Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?
Jan 27
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year
Dec 23Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)
Nov 18Shareholder Returns
| CYPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 284.0% | 3.2% | -0.2% |
| 1Y | -35.8% | 9.6% | 12.9% |
Return vs Industry: CYPH underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: CYPH underperformed the US Market which returned 12.9% over the past year.
Price Volatility
| CYPH volatility | |
|---|---|
| CYPH Average Weekly Movement | 105.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CYPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYPH's weekly volatility has increased from 56% to 105% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 26 | Doug Onsi | www.leaptx.com |
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
Cypherpunk Technologies Inc. Fundamentals Summary
| CYPH fundamental statistics | |
|---|---|
| Market cap | US$99.71m |
| Earnings (TTM) | -US$51.05m |
| Revenue (TTM) | n/a |
Is CYPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.05m |
| Earnings | -US$51.05m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CYPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 12:37 |
| End of Day Share Price | 2025/11/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cypherpunk Technologies Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Wangzhi Li | Ladenburg Thalmann & Company |
| Tyler Van Buren | Piper Sandler Companies |